Completion of radiotherapy for local and regional head and neck cancer in medicare

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 9, 2009, Pages 860-867

  Fesinmeyer, Megan Dann ^a   Mehta, Vivek ^b   Tock, Lauri ^a   Blough, David ^a,c   McDermott, Cara ^a   Ramsey, Scott D ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; LARYNX TUMOR; MAJOR CLINICAL STUDY; MALE; MOUTH TUMOR; NOSE CAVITY TUMOR; NOSE TUMOR; PHARYNX TUMOR; RELAPSE; SALIVARY GLAND TUMOR; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MEDICARE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT COMPLIANCE; PROBABILITY; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; REGISTRIES; RISK ASSESSMENT; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 70349331491     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.108     Document Type: Article

References (25)

1. American Cancer Society. Statistics for 2006. http://www.cancer.org/ docroot/STT/stt-0-2006.asp?sitearea=STT&level=1. Accessed August 14, 2007.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695-1709.
3. Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation? Head Neck. 2004;26(2):127-135. (Pubitemid 38160446)
4. Yao M, Dornfeld KJ, Buatti JM, et al. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma: the University of Iowa experience. Int J Radiat Oncol Biol Phys. 2005;63(2):410-421. (Pubitemid 41317157)
5. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131-146. (Pubitemid 18168463)
6. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16(3):831-843. (Pubitemid 19079722)
7. Dubben HH. Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol. 1994;32(3):197-200. (Pubitemid 2154166)
8. Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229-236. (Pubitemid 34899671)
9. Van den Bogaert W, Van der Leest A, Rijnders A, Delaere P, Thames H, van der Schueren E. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother Oncol. 1995;36(3): 177-182.
10. Rosenthal DI. Consequences of mucositis-induced treatment breaks and dose reductions on head and neck cancer treatment outcomes. J Support Oncol. 2007; 5(9)(suppl 4):23-31.
11. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope. 2008;118 (4):635-639.
12. Hutcheson KA, Barringer DA, Rosenthal DI, May AH, Roberts DB, Lewin JS. Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2008;134(2):178-183.
13. National Cancer Institute. SEER-Medicare: SEER Program & data. http: //healthservices.cancer.gov/seermedicare/aboutdata/program.html. Accessed June 23, 2008.
14. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40 (8)(suppl):IV49-IV54.
15. Bourhis J, Overgaard J, Audry H, et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006; 368(9538):843-854.
16. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Sta° hl E. A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 2003;42(5-6):443-461. (Pubitemid 37193837)
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
19. Montero EH, Trufero JM, Romeo JA, Terré FC. Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori. 2008; 94(1):24-29.
20. National Comprehensive Cancer Network. NCCN clinical guidelines in oncology: head and neck cancers, version 2. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed June 18, 2008.
21. Pivot X, Cals L, Cupissol D, et al. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology. 2001;60(1):66-71. (Pubitemid 32041434)
22. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88(1):11-17. (Pubitemid 36241211)
23. Nathan H, Pawlik TM. Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol. 2008;15(2):415-423.
24. Gritz ER, Carmack CL, de Moor C, et al. First year after head and neck cancer: quality of life. J Clin Oncol. 1999;17(1):352-360. (Pubitemid 29022414)
25. Das IJ, Cheng CW, Chopra KL, Mitra RK, Srivastava SP, Glatstein E. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst. 2008;100(5):300-307.